Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Aricept (Donepezil HCI) – US: Lawsuit alleges false marking based on Orange Book ‘advertising’: Pharmaceutical Technologies v Eisai (FDA Law Blog) (Patent Docs)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

What to do in the face of a patent cliff: A view from Medium Pharma (IP finance) (IP finance)

Study: Patent applications rise on flu genetic resources; questioning WIPO report (IP Watch)

WHO group strikes landmark deal on global framework for flu pandemics (IP Watch) (IP Watch)

Book explores intersection of policymaking in IP, biodiversity (IP Watch)

Australia: Painaway case reveals some painful IP licensing lessons: Painaway Australia v JAKL Group (IP Whiteboard)

Australia: Update on campaign against medical research funding cuts (Patentology)

Australia: New regulatory framework for biological will commence 31 May (GenericsWeb)

France: Supreme Court rules US doctrine of file wrapper estoppel not applicable under EPC: Institut Pasteur v Novartis (Kluwer Patent Blog)

India: Compulsory licensing discussion draws to an end (Spicy IP)

India: Hazare hunger and policy making – Indian “Bayh Dole” bill (Spicy IP)

US: Organic farmers file pre-emptive lawsuit challenging Monsanto’s patents on genetically modified seeds (IPKat)

US: House Judiciary Committee’s patent reform bill is in need of reform, says BIO (PatentlyBIOtech)

Products

Adderall XR (Dextroamphetamine sulfate, Dextroamphetamine saccharate, Amphetamine aspartate monohydrate, Amphetamine sulfate) – US: Shire files patent infringement suit against Watson in response to Para IV challenge (Patent Docs)

Amrix (Cyclobenzaprine) – US: District Court Delaware: Mylan, Barr and Anchen blocked from introducing generic Amrix: In re Cyclobenzaprine Hydrochloride Extended (Patent Docs)

Aricept (Donepezil HCI) – US: Lawsuit alleges false marking based on Orange Book ‘advertising’: Pharmaceutical Technologies v Eisai (FDA Law Blog) (Patent Docs)

Citalopram – UK: EWHC (Pat): Infosint’s patent relating to method of making 5-carboxyphthalide lacks inventive step; ‘public should not be expected to check the EPO register’: Lundbeck v. Infosint (IPKat) (PatLit)

Clobex (Clobetasol) – US: Galderma, Dermalogix agree to end Clobex suit with Paddock (Patent Docs)

Crestor (Rosuvastatin) – US: Palmetto files patent infringement suit against AstraZeneca based on its Crestor product; AstraZeneca files for declaratory judgment of non-infringement and invalidity (Patent Docs)

Drospirenone, Ethinylestradiol – UK: Shedding further light on obviousness: Gedeon Richter PC v Bayer Schering Pharma AG (Kluwer Patent Blog)

Ebastin – Belgium: Antwerp Commercial Court refuses preliminary injunction because patent holder could have started accelerated proceedings on the merits earlier: Almirall v Teva (Kluwer Patent Blog)

Esomeprazole – Germany: In preliminary injunction proceedings, Hamburg District Court finds respondents’ products would not infringe: AstraZeneca v. Teva and ratiopharm (EPLAW)

Fentanyl – Germany: Federal Court of Justice: Lessons to be learned for claim construction and novelty: Xa ZR 149/07 (Kluwer Patent Blog)

Finasteride – France: Tribunale de Grande Instance de Paris: Murder me twice – Merck’s dosage regime patent held invalid again: Teva v Merck Sharp & Dohme (EPLAW)

Gaviscon (Sodium alginate, Sodium bicarbonate, Calcium carbonate) – UK: Reckitt Benckiser fined £10.2 M for halting supply of heartburn medicine to NHS to block sales of generic version (GenericsWeb)

Remicade (Infliximab), Simponi (Golimumab) – Global: Merck and Johnson & Johnson reach agreement on distribution rights for Remicade and Simponi (GenericsWeb)

Synvisc (Hyaluronan) – US: Genzyme files patent suit against Seikagku and Zimmer over Synvisc (GenericsWeb)

Treximet (Sumatripan, Naproxen) – US: E D Texas orders preliminary injunction against Par Pharmaceutical in Pozen Treximet patent litigation (GenericsWeb)

Vancocin (Vancomycin) – US: ViroPharma’s preemptive strike over generic Vancocin fails; District Court grants FDA’s motion to dismiss (FDA Law Blog)

Vigamox (Moxifloxacin) – US: Alcon files patent infringement complaint against Watson in response to Para IV patent challenge (Patent Docs)